Elanco Animal Health (ELAN) Other Non-Current Assets (2017 - 2026)
Elanco Animal Health (ELAN) posted Other Non-Current Assets of $295.0 million for Q1 2026, down 2.96% sequentially from $304.0 million in Q4 2025, and down 5.45% YoY from $312.0 million in Q1 2025.
Elanco Animal Health (ELAN) Other Non-Current Assets (2017 - 2026) Analysis & Trends
Elanco Animal Health has reported Other Non-Current Assets for 10 years, with the latest figure at $295.0 million in Q1 2026.
- Quarterly Other Non-Current Assets fell 5.45% year-over-year to $295.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $295.0 million (down 5.45% YoY) and the FY2025 annual result came in at $304.0 million, down 2.25% from the prior year.
- Other Non-Current Assets fell to $295.0 million in Q1 2026 per ELAN's latest filing, from $304.0 million in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $559.0 million in Q1 2022 and troughed at $295.0 million in Q1 2026.
- A 5-year average of $355.1 million and a median of $341.0 million in 2023 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Assets soared 72.0% in 2022, then plunged 33.99% in 2023.
- Over 5 years, Other Non-Current Assets stood at $378.0 million in 2022, then dropped by 9.79% to $341.0 million in 2023, then declined by 8.8% to $311.0 million in 2024, then retreated by 2.25% to $304.0 million in 2025, then declined by 2.96% to $295.0 million in 2026.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $295.0 million, $304.0 million, and $306.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.85 Bn | 42.88 Bn | - | 56.35 Mn |
| 2 | Teva Pharmaceutical Industries | 43.31 Bn | 39.66 Bn | 2.15 Bn | 1.79 Bn |
| 3 | Zoetis | 31.65 Bn | 29.98 Bn | 1.05 Bn | 384.00 Mn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | 503.80 Mn |
| 5 | United Therapeutics | 22.18 Bn | 19.52 Bn | 683.80 Mn | 239.50 Mn |
| 6 | Viatris | 18.82 Bn | 17.94 Bn | 1.46 Bn | 1.06 Bn |
| 7 | Neurocrine Biosciences | 15.70 Bn | 15.31 Bn | 935.80 Mn | 59.30 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn | 304.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | 13.00 Mn |
| 10 | Alkermes | 8.21 Bn | 7.55 Bn | 397.90 Mn | 62.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 304.00 Mn |
| Mar 31, 2026 | 295.00 Mn |
| Dec 31, 2025 | 304.00 Mn |
| Sep 30, 2025 | 306.00 Mn |
| Jun 30, 2025 | 308.00 Mn |
| Mar 31, 2025 | 312.00 Mn |
| Dec 31, 2024 | 311.00 Mn |
| Sep 30, 2024 | 302.00 Mn |
| Jun 30, 2024 | 324.00 Mn |
| Mar 31, 2024 | 346.00 Mn |
| Dec 31, 2023 | 341.00 Mn |
| Sep 30, 2023 | 410.00 Mn |
| Jun 30, 2023 | 419.00 Mn |
| Mar 31, 2023 | 369.00 Mn |
| Dec 31, 2022 | 378.00 Mn |
| Sep 30, 2022 | 376.00 Mn |
| Jun 30, 2022 | 376.00 Mn |
| Mar 31, 2022 | 559.00 Mn |
| Dec 31, 2021 | 390.00 Mn |
| Sep 30, 2021 | 357.00 Mn |